This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Health product recall

Simplexa Flu A/B & RSV Direct

Last updated

Summary

Product
Simplexa Flu A/B & RSV Direct
Issue
Medical devices - Performance issue
What to do

Discontinue using remaining inventory, share recall notice with users, complete/return response form. 

Audience
Healthcare

Affected products

Affected products

Lot or serial number

Model or catalog number

Simplexa Flu A/B & RSV Direct

15279N

MOL2655

Issue

Customer complaints were received for disc leaks while running Simplexa Covid-19 Direct kit with assay definition version 2 (high spin & temp). Leakage was confirmed by retain testing on 1/6/22 with discs run on Covid-19 Direct assay definition version 2. No disc leakage occurred with version 3 (reduced spin & temp). Simplexa Flu A/B & RSV (mol2655) and Simplexa Covid-19 & Flu A/A Direct (mol4250) have similar assay definitions and are also at risk for leakage.

Recall start date: February 01, 2023

Additional information

Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Medical devices - Microbiology
Companies

Diasorin Molecular LLC

11331 Valley View Street, Cypress, California, United States, 90630

Published by
Health Canada
Audience
Healthcare
Recall class
Type II
Identification number
RA-72668

Get notified

Receive notifications for new and updated recalls and alerts by category.

Subscribe